Fig. 2

MOMIPP selectively impairs glucose uptake compared to the non-cytotoxic analog, MOPIPP. a One day after plating, U251 cells were treated with 10 μM MOMIPP, 10 μM MOPIPP, or DMSO (control). Twenty four hours after addition of the compounds, the cellular uptake of [³H]2-DG was assayed as described in the Methods. The results are the mean (± SD) of determinations performed on three cultures, expressed as percent of the mean for the controls. b Uptake of [³H]2-DG was measured in multiple validated human glioblastoma cell lines, 24 h after addition of 10 μM MOMIPP. The results (mean ± SD, n = 3) are expressed as percent of the parallel controls. c [³H]2-DG uptake was assessed in U251 cells after a 2 h exposure to 10 μM MOMIPP or MOPIPP, with the results expressed as percent of the parallel DMSO controls (mean ± SD, n = 3). d A dose-response study was performed with U251 cells, measuring [³H]2-DG uptake 4 h after addition of the indicated concentrations of MOMIPP, with the results expressed as percent of the controls without drug (mean ± SD, n = 3). e Uptake of [³H]2-DG was compared in U251 cells and normal human skin fibroblasts at 4 h and 24 h after treatment with 10 μM MOMIPP. The results (mean ± SD, n = 3) are expressed as percent of the values in parallel controls treated with vehicle only (DMSO). f One day after plating, U251 cells were treated with 10 μM MOMIPP or an equivalent volume of DMSO for 4 h, and ⁸⁶Rb uptake was measured as described in the methods (mean ± SD, n = 3)